Marked expression of plasma brain natriuretic peptide is a special feature of hypertrophic obstructive cardiomyopathy

Second Department of Internal Medicine, Gifu University, Japan.

OBJECTIVES: We examined whether plasma brain natriuretic peptide levels are abnormally elevated in hypertrophic obstructive cardiomyopathy compared with other cardiac diseases. BACKGROUND: We previously reported that plasma brain and atrial natriuretic peptide levels were elevated in hypertrophic cardiomyopathy. METHODS: We compared plasma concentrations of brain and atrial natriuretic peptide and hemodynamic and echocardiographic data in 50 patients with hypertrophic obstructive cardiomyopathy (n = 15, mean [+/-SD] intraventricular pressure gradient 37 +/- 16 mm Hg), hypertrophic nonobstructive cardiomyopathy (n = 15), aortic stenosis (n = 10, mean pressure gradient 41 +/- 18 mm Hg) and hypertensive heart disease (n = 10, mean systolic/diastolic blood pressure 203 +/- 16/108 +/- 11 mm Hg, respectively) and 10 normal subjects. RESULTS: Plasma brain natriuretic peptide levels were higher in the hypertrophic obstructive cardiomyopathy group (397.1 +/- 167.8 pg/ml*) than in the hypertrophic nonobstructive cardiomyopathy (60.0 +/- 48.1 pg/ml*), hypertensive heart disease (53.9 +/- 31.4 pg/ml*), aortic stenosis (75.4 +/- 54.3 pg/ml*) and normal groups (9.8 +/- 6.4 pg/ml [*p < 0.05 vs. normal group, p < 0.05 vs. hypertrophic obstructive cardiomyopathy group]). Although plasma atrial natriuretic peptide levels were higher in the hypertrophic obstructive cardiomyopathy group than the other patient groups, the brain/atrial natriuretic peptide ratio in the hypertrophic obstructive cardiomyopathy group was higher (4.5 +/- 2.3) than those in the other three patient groups (1.1 to 1.4) and the normal group (0.7 +/- 0.5). Left ventricular end-diastolic pressure and left ventricular end-diastolic volume index were similar among the four patient groups. The interventricular septal thickness and the ratio of interventricular septal thickness to left ventricular posterior wall thickness were similar between the hypertrophic obstructive and nonobstructive cardiomyopathy groups. CONCLUSIONS: Abnormal elevations of plasma brain natriuretic peptide levels are difficult to explain on the basis of hemodynamic and echocardiographic data and are a special feature of hypertrophic obstructive cardiomyopathy.

This article has been cited by other articles:

				F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis Eur. Heart J., January 9, 2009; (2009) ehn538v1. [Abstract] [Full Text] [PDF]

				S. Kido, N. Hasebe, Y. Ishii, and K. Kikuchi Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1064 - H1070. [Abstract] [Full Text] [PDF]

				R. Talens-Visconti, M. Rivera Otero, M. J. Sancho-Tello, F. G. de Burgos, L. Martinez-Dolz, B. Sevilla, V. Climent, R. Cortes, A. Salvador, F. Sogorb, et al. Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure Eur J Echocardiogr, January 1, 2006; 7(1): 45 - 52. [Abstract] [Full Text] [PDF]

				H. Shimizu, Y. Murakami, S.-i. Inoue, Y. Ohta, K. Nakamura, H. Katoh, T. Sakne, N. Takahashi, S. Ohata, T. Sugamori, et al. High Plasma Brain Natriuretic Polypeptide Level as a Marker of Risk for Thromboembolism in Patients With Nonvalvular Atrial Fibrillation Stroke, April 1, 2002; 33(4): 1005 - 1010. [Abstract] [Full Text] [PDF]

				M Nakamura, H Endo, M Nasu, N Arakawa, T Segawa, and K Hiramori Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population Heart, February 1, 2002; 87(2): 131 - 135. [Abstract] [Full Text] [PDF]

				W.J. Paulus Natriuretic peptides to probe haemodynamic overload in hypertrophic cardiomyopathy Eur. Heart J., August 1, 2001; 22(15): 1249 - 1251. [Abstract] [PDF]

				C Briguori, S Betocchi, F Manganelli, B Gigante, M.A Losi, Q Ciampi, R Gottilla, A Violante, C.G Tocchetti, M Volpe, et al. Determinants and clinical significance of natriuretic peptides and hypertrophic cardiomyopathy Eur. Heart J., August 1, 2001; 22(15): 1328 - 1336. [Abstract] [PDF]